Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery
- PMID: 24554118
- DOI: 10.1007/s11095-014-1312-8
Pharmacokinetic comparison between the long-term anesthetized, short-term anesthetized and conscious rat models in nasal drug delivery
Abstract
Purpose: To investigate the pharmacokinetic differences between the common nasal delivery models.
Methods: In three different rat models [long-term anesthetized (with nasal surgery), short-term anesthetized (without nasal surgery) and conscious models], tacrine and loxapine were administered via nasal, intravenous and oral routes, and the plasma pharmacokinetics were compared among different models.
Results: Systemic exposures of both drugs and their metabolites were consistently higher in long-term anesthetized model after all routes of administration in comparison to that of conscious model. Nasal bioavailabilities in long-term anesthetized model (tacrine 83%, loxapine 97%) were much higher than that in conscious model (tacrine 10%, loxapine 46%). Further studies on tacrine and its metabolites demonstrated no significant difference in t1/2 between short-term anesthetized and conscious models after all routes of administration; however, long-term anesthetized model showed significantly longer t1/2. Regarding the pharmacokinetic parameters (Cmax, Tmax, AUC, bioavailability) of tacrine and its metabolites, short-term anesthetized model resembled closer to conscious model than long-term anesthetized model.
Conclusions: Plasma clearances of tacrine, loxapine, and their metabolites were much slower in the long-term anesthetized model of nasal delivery probably due to suppressed hepatic and renal clearances, while the short-term anesthetized model imposed less impact on tacrine pharmacokinetics and metabolism.
Similar articles
-
Brain disposition and catalepsy after intranasal delivery of loxapine: role of metabolism in PK/PD of intranasal CNS drugs.Pharm Res. 2013 Sep;30(9):2368-84. doi: 10.1007/s11095-013-1080-x. Epub 2013 Jun 7. Pharm Res. 2013. PMID: 23739987
-
Development, characterization and application of in situ gel systems for intranasal delivery of tacrine.Int J Pharm. 2014 Jul 1;468(1-2):272-82. doi: 10.1016/j.ijpharm.2014.04.015. Epub 2014 Apr 5. Int J Pharm. 2014. PMID: 24709220
-
Nose-to-brain delivery of tacrine.J Pharm Pharmacol. 2007 Sep;59(9):1199-205. doi: 10.1211/jpp.59.9.0003. J Pharm Pharmacol. 2007. PMID: 17883890
-
Intranasal mucoadhesive microemulsion of tacrine to improve brain targeting.Alzheimer Dis Assoc Disord. 2008 Apr-Jun;22(2):116-24. doi: 10.1097/WAD.0b013e318157205b. Alzheimer Dis Assoc Disord. 2008. PMID: 18525282 Review.
-
Clinical pharmacokinetics of tacrine.Clin Pharmacokinet. 1995 Jun;28(6):449-57. doi: 10.2165/00003088-199528060-00003. Clin Pharmacokinet. 1995. PMID: 7656503 Review.
Cited by
-
The Role of Inhaled Loxapine in the Treatment of Acute Agitation in Patients with Psychiatric Disorders: A Clinical Review.Int J Mol Sci. 2017 Feb 8;18(2):349. doi: 10.3390/ijms18020349. Int J Mol Sci. 2017. PMID: 28208695 Free PMC article. Review.
-
The development and validation of an HPLC-MS/MS method for the determination of eriocitrin in rat plasma and its application to a pharmacokinetic study.RSC Adv. 2020 Mar 12;10(18):10552-10558. doi: 10.1039/c9ra10925k. eCollection 2020 Mar 11. RSC Adv. 2020. PMID: 35492908 Free PMC article.
-
Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.J Clin Pharmacol. 2019 May;59(5):731-747. doi: 10.1002/jcph.1365. Epub 2019 Jan 24. J Clin Pharmacol. 2019. PMID: 30676661 Free PMC article.
-
Significantly Increased Aqueous Solubility of Piperine via Nanoparticle Formulation Serves as the Most Critical Factor for Its Brain Uptake Enhancement.Int J Nanomedicine. 2025 Mar 30;20:3945-3959. doi: 10.2147/IJN.S506827. eCollection 2025. Int J Nanomedicine. 2025. PMID: 40181831 Free PMC article.
-
Demonstration of Direct Nose-to-Brain Transport of Unbound HIV-1 Replication Inhibitor DB213 Via Intranasal Administration by Pharmacokinetic Modeling.AAPS J. 2017 Dec 27;20(1):23. doi: 10.1208/s12248-017-0179-0. AAPS J. 2017. PMID: 29282567
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical